DPTX 3186
Alternative Names: DPTX-3186Latest Information Update: 02 Dec 2024
Price :
$50 *
At a glance
- Originator Dewpoint Therapeutics
- Developer Dewpoint Therapeutics; Evotec SE
- Class Antineoplastics; Small molecules
- Mechanism of Action Beta catenin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer